Biota Pharmaceuticals Inc Share Price Nasdaq
Equities
US6295191091
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
13/05 | Transcript : Vaxart, Inc., Q1 2024 Earnings Call, May 13, 2024 | |
13/05 | Vaxart, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Sales 2024 * | 1.47Cr 122.96Cr | Sales 2025 * | 2.31Cr 192.79Cr | Capitalization | 18Cr 1.51TCr |
---|---|---|---|---|---|
Net income 2024 * | -7.7Cr -642.64Cr | Net income 2025 * | -8Cr -667.68Cr | EV / Sales 2024 * | 12.2 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 7.81 x |
P/E ratio 2024 * |
-2.25
x | P/E ratio 2025 * |
-2.59
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.5% |
Latest transcript on Biota Pharmaceuticals Inc
Managers | Title | Age | Since |
---|---|---|---|
Sean Tucker
FOU | Founder | - | 01/04/01 |
Phillip Eric Lee
DFI | Director of Finance/CFO | 37 | 19/22/19 |
Michael Finney
CHM | Chairman | 65 | 01/07/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Yedid
BRD | Director/Board Member | 66 | 25/19/25 |
Elaine Heron
BRD | Director/Board Member | 76 | 25/22/25 |
Michael Finney
CHM | Chairman | 65 | 01/07/01 |
1st Jan change | Capi. | |
---|---|---|
+8.29% | 11TCr | |
+10.21% | 10TCr | |
+0.41% | 2.23TCr | |
-11.90% | 2.24TCr | |
-5.99% | 1.91TCr | |
-37.36% | 1.8TCr | |
-5.17% | 1.79TCr | |
+7.70% | 1.43TCr | |
+37.65% | 1.25TCr |